OSTEOPORE LIMITED(OSX)

The suspension of trading in the securities of Osteopore Limited will be lifted from the commencement of trading on Tuesday, 8 April 2025 following lodgement of its Annual Financial Report for the year ended 31 December 2024.

The company lodges its annual report to shareholders, appendix 4G, and corporate governance statement.

The company has entered into a subscription agreement with Advance Opportunities Fund and Advance Opportunities Fund I. The company plans to issue 4.0% redeemable convertible notes with an aggregate nominal value of up to A$20,000,000.

Entities' securities will be suspended from quotation under Listing Rule 17.5 due to non-filing of a periodic report. If lodged between market announcements office closure and suspension, securities will be reinstated.

The suspension of trading in the securities of Osteopore Limited will be lifted from the commencement of trading on Wednesday, 17 April 2024 following lodgement of its Annual Report for the year ended 31 December 2023.

The company lodges its Annual Report to Shareholders.

The company releases its Appendix 4G and Corporate Governance Statement.

The company releases a response to ASX Query Letter.

The maturity date of the Bridging Loan was ninety calendar days from the disbursement date. The Company has entered a variation deed on 9 April 2024 with the Lender to extend the maturity date of the Bridging Loan to 1 May 2025. The Bridging Loan interest rate under the Variation Deed has changed from 3% per month in the initial three months, 4% per month in the fourth month and 5% per month in the fifth month and thereafter, to 3% per month calculated on a daily rest basis and payable on the first business day of each month. Notwithstanding any other provisions to the Variation Deed, the Company has the option to make early repayments to the Bridging Loan at any time. Other Bridging Loan terms and conditions remain unchanged.

The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024.

The company's AGM will be held on 30 May 2024. Any nominations for directors must be received at the company's registered office no later than 5:00pm (WST) on 18 April 2024.

The company releases an updated notice of proposed issue of securities.

The Renounceable Pro-Rata Entitlement Offer and Shortfall Offer to raise ~A$3,000,000 (before costs) closed on 2 April 2024 with strong support from eligible shareholders.

The company releases an updated notice of proposed issue of securities.

The company releases a replacement prospectus for Renounceable Rights Issue.

The company releases a notice of proposed issue of securities.

The company releases a letter to its eligible shareholders regarding the entitlement offer.

The Company releases a replacement entitlement offer prospectus for a renounceable pro rata offer to Eligible Shareholders of approximately 103,286,890 New Shares at an issue price of $0.029 per New Share on the basis of 10 New Share for every 1 Existing Shares with 1 free attaching New Option for every 5 New Shares acquired to raise up to $3,000,000 before costs. This Prospectus is also being issued for the Shortfall Offer described in this Prospectus.

The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of its Annual Report.

The suspension of the following options of Osteopore Limited ("˜will be lifted immediately following ASX being satisfied that there is a sufficient spread of option holders for the purposes of Listing Rule 2.5 condition 6: OSXO

The following Options of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.3: OSXO.

The suspension of trading in the securities of Osteopore Limited will be lifted immediately following the release by OSX of an announcement regarding a capital raising.

The company releases a notice of proposed issue of securities.

Osteopore has received binding commitments from sophisticated and existing investors for a total A$1,000,000 Placement at $0.15 per share, with one (1) free attaching option for every one (1) new share subscribed for. Proceeds from the Placement will be used to support sales momentum, develop and launch new breakthrough products, secure regulatory clearances in new markets and provide capacity for continued exploration of potential partnerships and acquisition opportunities aimed at increasing company value. The Company has entered into a non-binding term sheet with Mr Lim Jae Hoon for the proposed acquisition of 100% of the businesses owned by Lomic Korea Co., Ltd, 3D Aesthetic Solutions Pte Ltd, 3D Healthcare Solutions Co., Ltd and 3D Aesthetic Medical Equipment and Supplies Trading in order to increase the distribution of Osteopore products.

The securities of Osteopore Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of an announcement regarding a capital raising.

listed entity carried for record purposes only